Jump to content

Talarozole

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 08:46, 8 September 2016 (Updating {{infobox_drug}} (changes to verified fields - updated 'ChEBI_Ref') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Talarozole
Clinical data
Routes of
administration
oral, topical
ATC code
  • none
Identifiers
  • N-(2-Benzothioazolyl)-N-[4-[2-ethyl-1-(1,2,4-triazo-1-yl)butyl]phenyl]amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23N5S
Molar mass377.505 g/mol g·mol−1
3D model (JSmol)
  • c2ncnn2C(C(CC)CC)c(cc3)ccc3Nc4nc1ccccc1s4
  • InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25) ☒N
  • Key:SNFYYXUGUBUECJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Talarozole (formerly R115866, planned trade name Rambazole) is an investigational drug for the treatment of acne, psoriasis and other keratinization disorders.

Talarozole inhibits the metabolism of retinoic acid by blocking the cytochrome P450 enzyme isoform CYP26, a retinoic acid hydroxylase. Because of this mechanism, it is called a retinoic acid metabolism blocking agent (RAMBA).[1]

References

  1. ^ Giltaire, S; Herphelin F; Frankart A; Hérin M; Stoppie P; Poumay Y (11 December 2008). "The CYP26 inhibitor R115866 potentiates the effects of all-trans retinoic acid on cultured human epidermal keratinocytes". Br J Dermatol. 160 (3): 505–13. doi:10.1111/j.1365-2133.2008.08960.x. PMID 19120344.